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CNS active O-linked glycopeptides
Evan M. Jones and Robin Polt *
Robin Polt Lab, Department of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ, USA
Naturally occurring glycopeptides and glycoproteins play important roles in biological
processes. Glycosylation is one of the most common post-translational modifications
in vivo. Glycopeptides are involved in cell signaling and sorting, providing cell surface
markers for recognition. From the drug design and synthesis perspective, modification
of a peptide through glycosylation results in increased bioavailability and bioactivity
of glycopeptides in living systems with negligible toxicity of degradation products.
Glycopeptide synthesis can be accomplished through incorporation of a glycosylated
amino acid in solid phase peptide synthesis (SPPS) to form the desired peptide,
or via incorporation of sugar-amino acid moieties. Additionally, research indicates
that glycosylation increases penetration of the blood-brain barrier (BBB) by peptides,
which may lead to novel therapeutics for neurological disorders. Recent applications
of glycopeptides have focused on the in vivo central nervous system (CNS) effects
after peripheral administration of centrally active peptides modified with various
carbohydrates.
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Introduction
Endogenously derived peptides are attractive as a source of drugs due to their potent and
highly selective interactions with G-protein coupled receptors (GPCRs), combined with their
very low levels of toxicity (Kaspar and Reichert, 2013; Fosgerau and Hoffmann, 2015). The
presence of proteolytic degradation pathways for peptides suggests that “off target” effects produced
by metabolites will be minimal. In contrast, classical “small molecule” drugs are frequently
promiscuous, leading to unpredicted off-target interactions as well as toxic metabolites (Rao and
Mohamed, 2011). These same proteolysis pathways also represent a challenge since many peptides
exhibit serum half-lives of only a few minutes (Fosgerau and Hoffmann, 2015). In addition,
because drug development generally revolves around the synthesis and modification of small,
organic molecules, peptide drugs do not fit within most of the widely accepted “rules” governing
modulation of distribution, metabolism, and pharmacokinetic effects (DMPK), and therefore
classical drug design strategies are ineffective (Lipinski et al., 2001). Peptides also necessitate careful
handling and optimization of a separate set of challenges, including membrane transport, and
the previously noted ease of metabolism and degradation. For peptide drug candidates targeted
to the central nervous system (CNS), crossing the blood-brain barrier (BBB) is a challenge
due to tight junctions, and is home to several peptidases (Egleton et al., 2000). Therefore,
modifications to peptides to alter their DMPK have been widely explored (Diao and Meibohm,
2013). One modification that has shown much promise in recent years is glycosylation: appending
a carbohydrate moiety along the peptide backbone to form glycopeptides. This is traditionally
performed through O-linked, N-linked, C-linked, and more recently, S-linked (Zhu et al., 2003;
Whalen and Halcomb, 2004) glycoside formation, as well as the synthesis and integration of
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“sugar amino acids” into peptides (Chakraborty et al., 1998;
Prasad et al., 2005; Simone et al., 2005; Risseeuw et al., 2013).
While examples of each can be found in nature and in the
laboratory, this review will focus on O-linked glycopeptides.
Alternate modifications including phosphorylation of peptides
(Yeomans et al., 2011) and development of cyclic peptides have
also been shown improve their drug-like properties, although
those are not the focus of this review.
Glycopeptides play a wide range of roles in the regulation
of many biochemical functions (Taylor, 1998). Notably, these
include cell signaling and immune system response (Rudd
et al., 2001). Additional post-translational modifications can
provide both N-linked and O-linked glycoproteins through
further elaboration by glycosyltransferases (Penno et al.,
1989; Hennet, 2002; Cohen and Varki, 2014). In medicine,
glycopeptide antibiotics such as vancomycin and bleomycin A2
are effective treatments of methicillin-resistant Staphylococcus
aureus (MRSA) and Hodgkin’s lymphoma, respectively.
In some cases however, glycopeptides can produce adverse
effects. For instance, Rudd and coworkers described an
overexpression of a glycoprotein, MUC1, in patients with
breast cancer (Storr et al., 2008). They hypothesized that the
increased presence of sugars on epithelial cell surfaces, from
glycoproteins and glycolipids, was responsible for decreased
immune responses. While it was noted that different types
of breast cancer each had different aberrations [for instance,
purified MUC1 from T47D breast cancer cell lines has primarily
core 1 type O-glycans, while MUC1 from MCF-7 is composed
of core 2 type O-glycans (Muller and Hanisch, 2002)], all breast
cancer cell lines displayed an increased number of carbohydrates
per glycoprotein when compared with healthy cells.
Benefits and Disadvantages of
Carbohydrate Incorporation
The benefits of glycosylation toward increasing drug-like activity
of peptides are manifold: in general carbohydrates improve
peptide DMPK within living systems, all without introducing
toxic compounds or metabolites.
Stability
Glycosylation of peptides can reduce their susceptibility to
enzymatic degradation. Enzyme binding pockets in proteases
need unhindered access to the target site on the peptide, allowing
selective cleavage of the peptide backbone. Due to their steric
bulk, carbohydrates directly bound to the amino acid that is
recognized by the protease can interfere with this binding,
reducing or completely eliminating proteolysis by that enzyme.
Carbohydrate placement on proximal or adjacent amino acids
may lead to reduced availability of the targeted peptide for
protease binding (such as the binding of trypsin to Lys or
Arg residues). Glycosylation at or near the N-terminus (NT)
can inhibit the activity of dipeptidyl peptidase IV (DPP-IV)
(Werle and Bernkop-Schnurch, 2006), but because in GPCR-
agonist peptides theNT is generally associated with the “message”
segment of a peptide and receptor activation, this can lead to a
concurrent decrease in activity. Modifications such as inversion
of the second amino acid (from L to D) can mitigate DPP-IV
activity.
Helical peptide conformations, as well as other tertiary
structures, impede the binding of some proteases. Some early
studies suggested that glycosylation of peptides may inhibit helix
formation in aqueous environments (Bertozzi et al., 1992). Early
work by Polt and coworkers to address this concern suggested
that some disruption of helical systems can occur; althoughmuch
of their model peptide was locked as a helix via a disulfide
bridge, the amino acid closest to the carbohydrate appeared less
helical than its non-glycosylated analog (Kriss et al., 2000). Later,
Polt and coworkers demonstrated that helicity of a peptide is
more strongly associated with the peptide sequence than with
the presence or absence of a carbohydrate (Palian et al., 2001).
In that experiment, a peptide known to evidence helicity in
aqueous conditions was modified with a serine residue, which
had previously been shown to reduce helical character (Merutka
and Stellwagen, 1990), and with a serine α-mannoside. NMR and
CD data collected on the peptides showed minimal variations in
helicity between the two peptides, although both were less helical
than the unmodified peptide.
Subsequent experiments have yielded opposing views on the
disruption of helicity by carbohydrates. Glycosylation of a series
of endorphins showed that the measured amount of helicity of a
peptide can be impacted by the peptide’s glycosylation state (Li
et al., 2012). In that study, the non-glycosylated peptide is helical,
but the addition of a monosaccharide disrupts the helicity, and
increasing the carbohydrate size to a disaccharide leads to further
decreases in helicity (although the glycopeptides remain active).
Other work showed that glycosylation appears to only have a
minimal effect on the helical nature of α-helical (Palian et al.,
2003; Li et al., 2014b) and coiled coil glycopeptides (Falenski
et al., 2010), and in some cases may stabilize the peptide’s tertiary
structure (Andersson et al., 1998). Therefore, when a helical
system is required in a peptide, studies must be made on a case-
by-case basis to determine if glycosylation will affect the peptide
secondary structure. Jensen and coworkers took into account
these considerations while designing and running a targeted
“glycoscan” (substituting native peptides for either a serine
glucoside or serine galactoside) of analogs of PYY3-36, a peptide
implicated as a potential therapeutic for obesity (Pedersen
et al., 2010). The researchers noted that selective installation of
carbohydrates increased the half-life of their peptides against two
proteases, while affecting helicity (both positively and negatively)
and receptor affinity in a site-dependent manner.
Distribution, Metabolism, and Pharmacokinetic
Effects
Autocrine and paracrine peptides are produced near their related
receptors, and all are quickly recycled, regardless of whether
or not receptor activation occurs. Endocrine peptides, which
travel via the bloodstream have longer half-lives, but are also
susceptible to enzymatic degradation mechanisms. In the context
of our highly regulated bodies, many endogenous peptides are
produced nearby to their related receptors (D’Souza et al., 2004).
Any peptides that do not perform their designed function are
quickly recycled by various enzymatic mechanisms, Modi (1994)
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preventing peptides from interacting with receptors in other
areas. For peptide drugs, this proves a sizeable barrier, as the
ideal pathways for introducing peptides to the body, via oral or
nasal administration, often leave them far removed from their
desired locations of activity (Fosgerau and Hoffmann, 2015).
Many peptides have serum half-lives in vivo similar to the
time it takes a blood cell to circulate through the bloodstream
(1–1.5min), reducing the chance that an exogenous peptide
will ever reach its destination. Therefore, prolonging the serum
half-life is imperative for improving the chances of the peptide
reaching its desired target. For oral administration, most peptides
do not have dedicated mechanisms for crossing membranes, a
number of which are present along the pathway from mouth
to brain.
One of the earliest indications that glycosylating compounds
targeted at the CNS may improve their pharmacokinetics was
the observation that morphine-6-glucuronide and morphine-
3-glucuronide improve the in vivo bioavailability of morphine
(as a µ-opioid receptor agonist and antagonist, respectively)
(Osborne et al., 1988; Mulder, 1992). Since then, multiple groups
have shown that glycosylation of a peptide increases membrane
penetration, both in the intestinal tract (Nomoto et al., 1998),
and the blood-brain barrier (BBB) (Poduslo and Curran, 1994;
Polt et al., 1994; Dhanasekaran and Polt, 2005; Egleton et al.,
2005; Otvos et al., 2008). It had been initially hypothesized that
glycosylation of peptides increases BBB penetration by exploiting
carbohydrate transporters such as glucose transporter GLUT-
1 (Polt et al., 1994), but this was later shown to be incorrect
(Li et al., 2012). In fact, Rocchi and coworkers observed that
their galactose-modified peptide entered the neurovascular unit
twice as rapidly as the glucose analog. (Negri et al., 1998)
Polycationic peptides may cross via adsorptive transcytosis,
(Figure 1) in which the positively charged peptide associates with
the negatively charged head groups of a membrane, a vesicle is
formed around it, and the peptide is delivered to the other side
of the membrane (Herve et al., 2008). It is also hypothesized
that peptides find transmembrane receptors by performing a two-
dimensional “search” of the membrane. As shown in Figure 2,
peptides that exist in a random coil in aqueous environs adopt
a helical conformation upon association with a membrane, and
subsequently “search” for a matched receptor. As equilibrium
exists for a peptide between its presence as either a membrane-
bound helix or a random coil, modulation of amphipathicity may
affect the amount of time a peptide spends in each state. This can
be altered through the addition of a highly hydrophilic moiety
such as a carbohydrate to a peptide (which trend hydrophobic),
andmay improve a peptide’s affinity for the aqueous environment
than its non-glycosylated analog. In turn, this may allow a
glycopeptide to interrogate a larger membrane surface are, and
increase the likelihood of finding a receptor (Li et al., 2012), as
seen in Figure 3.
Justification for increased bioavailability to the brain was
proposed by Polt and coworkers through what they term
“biousian” (bi—two, and ousia—essence) behavior: essentially
a measure of peptide amphipathicity, generally as the ratio of
the hydrophilic glycoside to the relatively hydrophobic peptide
backbone (Egleton et al., 2005). This hypothesis was further
encouraged experimentally by observations that i.v. activity of
modified glycopeptides adopts roughly a “U-shape” (Figure 4)
when plotted against computationally-derived Connolly surface
areas (e−Awater/Alipid) amphipathicity (Lowery et al., 2007).
In short, appending a small carbohydrate to a neuropeptide
decreased the i.v. A50-value, but as the size of the carbohydrate
increased the A50-value did as well. This suggests that addition of
FIGURE 1 | Adsorptive mediated transcytosis as pathway for BBB
penetration. Positively charged peptides in the bloodstream (1)
associate with the negatively charged membrane surface, thereby
inducing membrane invagination and vesicle formation. The
peptide-containing vesicle (2) then enters the intracellular space, and
may reintegrate with the CNS-side of the membrane (3), releasing the
peptides. Adapted from personal communications with Dr. Bobbi
Anglin.
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FIGURE 2 | Peptide-membrane interaction. In the presence of a membrane, a glycopeptide adopts a helical conformation and undergoes a two-dimensional
“search” of the membrane exterior. If the message segment interacts with a matched receptor, binding and activation occurs.
FIGURE 3 | Proposed mechanism of membrane “hopping.” In the
CNS, a peptide will be present in equilibrium between two primary
conformations: a random coil in aqueous environments, and a helix on a
membrane surface. This equilibrium is governed by the peptide’s
ampipathicity: the proportion of the peptide that is hydrophilic vs. that
which is hydrophobic. Theoretically, a glycopeptide will have a higher affinity
for the aqueous environment than its non-glycosylated analog, leading to
reduced time spent on the membrane surface. This is hypothesized to lead
to longer “hops,” presumably allowing a glycopeptide to interrogate more of
a membrane surface and find receptors.
a small carbohydrate allowed the peptide to probe a larger surface
area for receptors through “hopping,” but larger carbohydrates
displayed too strong a preference for the aqueous environment,
and not the membrane where receptors are located.
Finally, it is worth noting that some animals use glycosylated,
neurotoxic peptides as a self-defense mechanism. Many cone
snails use a glycosylated conotoxins to paralyze attackers (Gerwig
et al., 2013). Olivera and coworkers (Craig et al., 1999), among
others, synthesized non-glycosylated versions of a number of
these peptides, and found that although the non-glycosylated
versions showed improved neurotensin receptor binding affinity
compared with the native, glycosylated peptides, the native
peptides still showed a greater than 10-fold increase in i.v.
activity. This strongly suggests that the decreased enzymatic
degradation afforded by the glycosylated peptide is significant
enough that evolutionarily developing the glycopeptide was
preferred over its simpler, non-glycosylated analog (Craig et al.,
2001).
Synthetic Methods of O-linked
Carbohydrate Incorporation
O-linked carbohydrates are of particular interest in glycopeptide
development due to the frequency with which amino acids that
have hydroxyl-terminated side chains appear in living systems.
Synthetic glycopeptides are commonly prepared using solid-
phase peptide synthesis (SPPS) fluorenylmethyloxycarbonyl
(Fmoc) chemistry methodology (Polt et al., 1992; Lefever et al.,
2012). Sugars including glucose, lactose, galactose, mannose,
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FIGURE 4 | I.v. activity of DAMGO analogs vs. ampipathicity from
Lowery et al. (2007). A series of DAMGO analogs [in order of
increasing hydrophilicity: DAMGO, DAMGO-Ser(OH), DAMGO-Ser(OXyl),
DAMGO-Ser(OGlc), DAMGO-Ser(OLac)] were tested for i.v. MOR activity
using mouse tail-flick tests (Lowery et al., 2007). It was observed that
initial increases to hydrophilicity significantly improved activity, but
subsequent increases led to a decrease. This is believed to be the
result of the peptides spending a preponderance of time in the
aqueous phase, providing reduced opportunities for MOR binding and
activation.
xylose, glucosamine, and galactosamine have been affixed to the
amino acids serine, threonine, and hydroxyproline (Rodriguez
et al., 1989). It has been reported that glycosylated amino acids
are more likely to epimerize during SPPS (Zhang et al., 2012b)
but modifications including reagent selection and substitution
of similar amino acids, for instance Thr for Ser, can reduce this
undesirable side reaction (Zhang et al., 2012a). Li and coworkers
have also shown that ionic liquids can be used in place of resin
during glycopeptide syntheses (Li et al., 2014a).
Early O-glycosylation of amino acids, reviewed in a number
of places, Meldal and St Hilaire (1997) and Herzner et al. (2000)
typically used a Koenigs-Knorr approach to form the glycosyl
bond. In this methodology, strong Lewis acids are used to
displace a previously installed leaving group, typically a halide,
at the anomeric position to form an oxonium. The nucleophile,
in most cases the free hydroxyl of an Fmoc-protected amino
acid, then forms a bond at carbon-1, leading to either the
α or β anomer. By incorporating a directing group on the
adjacent carbohydrate hydroxyl, bias toward either α- or β-O-
linked amino acids can be achieved. Other methods, including
those with Schiff base protected amino acids (Polt et al., 1992;
Mitchell et al., 2001) or using SnCl3(ClO4) to produce the linkage
between an acetylated carbohydrate and TMS-protected Fmoc-
amino acid (Broddefalk et al., 1994) have also been reported
as methodologies to improve α/β selectivity or provide more
amenable reaction conditions.
In our lab, O-linkages to amino acids are performed directly
between Fmoc-protected amino acids with unprotected side
chains and peracetylated sugars. Use of peracetylated sugars with
amino acids allows their incorporation at any location within
the peptide and time during the synthesis. The acetates can
be removed orthogonally at the completion of the synthesis
using hydrazine or Zemplén conditions prior to cleaving the
glycopeptide from resin using standard TFA-based cleavage
conditions. A weak Lewis acid, such as InBr3 or Bi(OTf)3, is used
catalytically to drive the reaction to completion within a couple
hours (Lefever et al., 2012).
Toth and coworkers have reported the use of
glycosyltransferases to enzymatically append a carbohydrate
to previously prepared lactosylated Leu-enkephalin (Simerska
et al., 2013; Christie et al., 2014). This preparation has led
to compounds that ultimately improve the binding of the
enkephalin analogs to their desired target, the asialoglycoprotein
receptor.
Development and Applications of
Neurologically Active Glycopeptides
As referenced earlier, glycoantibiotics such as vancomycin,
bleomycin A2, and the “Sushi” peptides (Ding et al., 2008) have
been used worldwide to treat millions. These examples show that
using glycopeptides as drugs can successfully overcome many of
Frontiers in Chemistry | www.frontiersin.org 5 June 2015 | Volume 3 | Article 40
Jones and Polt CNS active O-linked glycopeptides
the obstacles that prevent widespread use of non-glycosylated
peptides.
Opioids—Enkephalins
Some of the first chemistry to validate the hypothesis that
glycosylation of a neuropeptide improves its pharmacokinetic
profile was through the modification of enkephalins (Polt et al.,
1992, 1994). Enkephalins are endogenous pentapeptides that
are partially selective for the δ-opioid receptor (DOR). Polt and
coworkers modified an enkephalin analog, [D-Pen2,5]enkephalin
(DPDPE) (Polt et al., 1994). It was observed that glycosylation
significantly improved the intraperitoneal (i.p.) antinociceptive
effects of the peptides when compared to those of the non-
glycosylated version. Further work to expand the number
of amino acids and carbohydrates, including both mono-
and disaccharides, that could be introduced into synthetic
peptides gave evidence of the broad scope of modifications
possible based on this technology (Mitchell et al., 2001).
Concurrently, modifications to the native forms of enkephalin,
Leu-enkephalin (Bilsky et al., 2000), and Met-enkephalin
(Egleton et al., 2000), were also being performed. Similar
improvements to antinociception were observed, and additional
work demonstrated that these particular glycopeptides decreased
the drug dependence commonly associated with opioid
receptor agonists, while improving their central neurological
bioavailability. Later, Toth and coworkers reported that
glycosylations of Leu-enkephalin yielded increased binding to
the asialoglycoprotein receptor, a receptor endogenously targeted
by galactose-terminated glycoproteins (Simerska et al., 2013;
Christie et al., 2014).
Opioids—Endorphins
To a lesser extent, research has also been performed on
glycosylated endorphins, 31 amino acids endogenous µ-opioid
receptor (MOR) antagonists. One of these, β-endorphin, shares
the same five amino acids at the N-terminus (NT) as Met-
enkephalin, and was targeted for further studies. Due to its
length, β-endorphin was modified to test the necessity of
helicity for receptor binding, and determining how glycosylation
either assists or hinders helix formation (Li et al., 2012,
2014b). Various spacers, including γ-aminobutyric acid (GABA)
and δ-aminovaleric acid (DAVA), as well as unnatural amino
acids such as 2-aminoisobutyric acid (Aib) were introduced
to allow localized helicity. These studies confirmed that
amphipathicity is crucial to membrane association of peptides,
and that glycosylation provides a very important variation
to amphipathicity, presumably through an increase to its
hydrophilic nature. As the authors state, the amphipathicity
provided by the carbohydrate of a glycopeptide “appears essential
for the effective transport of these larger peptides across the BBB”
(Li et al., 2012).
Other CNS-active Peptides
Further modifications to enkephalins and endorphins led to
mixed MOR/DOR agonists, such as MMP-2200 (Palian et al.,
2003). Since its publication, MMP-2200 has shown to be
active both as an antinociceptive via mixed MOR/DOR opioid
agonism with activity in theµmol/kg range (Elmagbari et al.,
2004; Lowery et al., 2011) and in preclinical Parkinson’s
disease models by blocking induced hyper-kinesia (Yue et al.,
2011). The authors attribute the latter activity to reducing
the downstream effects of various dopamine agonists in
their models.
Rocchi and coworkers performed studies with glycosylated
dermorphin analogs (Negri et al., 1998, 1999). They noted
that the addition of carbohydrates afforded improved
DMPKs via reduced susceptibility to enzymatic degradation
and improved passage across the BBB. In one case they
observed that despite displaying lower affinity for the DOR
than native dermorphin, a galactosylated analog afforded
much better in vivo antinociception when administered
peripherally.
The potent MOR-selective agonist DAMGO [Tyr-ala-Gly-
(NMe)Phe-Glyol] was modified to test the membrane hopping
hypothesis introduced above (Lowery et al., 2007). The
antinociceptive activity of DAMGO was compared with a series
of increasingly hydrophilic glycosylated derivatives (Figure 4).
The researchers determined that the glycosylated DAMGO
analogs maintained their MOR selectivity, and after i.v.
administration the level of antinociception produced a “U-
shaped” curve, where the A50 decreased upon the addition of a
small carbohydrate, but as the size of the carbohydrate increased,
so too did the A50. Presumably this activity is due to the latter
molecules’ propensity to remain in aqueous solution as opposed
to in a membrane-bound state where receptor activation is
possible.
Mosberg and coworkers developed a combined cyclic
tetrapeptide that provided potent MOR agonist/DOR antagonist
(Purington et al., 2011) but like many peptides, it suffered
from poor CNS bioavailability. Upon appendage of a serine
glucoside to the C-terminus, their peptide exhibited i.v.
antinociceptive activity similar to that of morphine, without the
development of acute tolerance that is a major side effect of
morphine use.
The secretin family of peptides, including secretin, glucagon,
pituitary adenylate cyclase-activating polypeptide (PACAP), and
vasoactive intestinal peptide (VIP), are a series of closely related
peptides and receptors that have a wide range of central and
peripheral nervous system activities. Recently, VIP and PACAP
have been identified as potential modulators of CNS immune
system response (Waschek, 2013) which has ramifications
for neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease and chronic traumatic encephalopathy, and
for traumatic brain injuries and strokes. However, these peptides
do not cross the BBB in appreciable quantities. Rocchi and
coworkers performed a novel “glyco-scan” of VIP to increase its
metabolic stability (Dangoor et al., 2008). They discovered that all
glycosylated peptides showed some decrease in receptor affinity.
Only one of their modified peptides showed a significant increase
in stability toward trypsin. To date there are no published
reports of in vivo tests of glycosylated secretins, although
another group (Bourgault et al., 2011) has also recognized
the potential for glycosylation to improve the neuroprotective
behavior of PACAP.
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Future Directions and Applications
With the significant headway scientists have made in the field,
the future is bright for glycopeptides. Recently glycopeptides have
been incorporated into various types of nanoparticles (NPs). It
was reported that MMP-2200 had been successfully conjugated
to poly(lactic-co-glycolic acid) (PLGA) NPs (Tosi et al., 2011,
2014). Interestingly, these NPs increased BBB penetration of the
peptide, likely through a combination of protecting the peptides
from proteases in the bloodstream and along membranes, and
improving the rate of endocytosis across the BBB membrane.
Another group (Lotfipour et al., 2014) successfully loaded
vancomycin into PLGA NPs and demonstrated that although
the antibiotic loses some of its in vitro antimicrobial activity,
it is slowly released from NPs, perhaps providing a mechanism
maintain therapeutic levels of a glycopeptide over time. Other
work has involved the tethering of glycopeptides to gold NPs
(Parry et al., 2013; Tavernaro et al., 2015). In one instance,
tethered MUC1-glycopeptide antigens were shown to allow
the glycopeptides to bypass most of the immune system and
enzymatic degradation pathways, and represents an attractive
future pathway for drug delivery.
Finally, recent developments of analytical techniques have led
to new methodologies for measuring BBB penetration in vivo,
via microdialysis. Kennedy and coworkers demonstrated that
after i.p. co-injection of MMP-2200 and Leu-enkephalin, they
were able to collect dialysate from the dorsolateral striatum
that showed the presence of these peptides in the nM range
within 10min (Mabrouk et al., 2012). Use of microdialysis for
BBB penetration analysis is a very attractive option for two
reasons. First, it offers the ability to test multiple compounds
concurrently, in a single living system. Second, researchers may
perform multiple tests before sacrificing the animal, leading
to fewer rodents necessary to validate each new potential
therapeutic.
Taken together, the pioneering glycopeptide work described
herein combined with the diverse and imaginative applications
currently undergoing study in the field show that glycopeptide
research has diverse opportunities for continued advances in
drug discovery.
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